Đang chuẩn bị liên kết để tải về tài liệu:
CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Endocrine resistance is a major obstacle to optimal treatment effect in breast cancer. Some genetic markers have been proposed to predict response to aromatase inhibitors (AIs) but the data is insufficient. The aim of the study was to find new genetic treatment predictive markers of AIs. |

TÀI LIỆU LIÊN QUAN

Lack of association between polymorphisms in the CYP1A2 gene and risk of cancer: Evidence from meta-analyse

Combination analysis in genetic polymorphisms of drug metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population

CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients